Organogenesis (NASDAQ:ORGO) Upgraded by Wall Street Zen to “Buy” Rating

Organogenesis (NASDAQ:ORGO) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Sunday.

A number of other equities research analysts also recently weighed in on the stock. BTIG Research decreased their price target on shares of Organogenesis from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Weiss Ratings raised shares of Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a report on Friday, February 27th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $8.50.

Organogenesis Price Performance

Shares of ORGO stock opened at $2.79 on Friday. Organogenesis has a 12 month low of $2.61 and a 12 month high of $7.08. The company has a market capitalization of $358.91 million, a P/E ratio of 34.88 and a beta of 1.43. The stock has a 50 day moving average of $3.94 and a two-hundred day moving average of $4.52. The company has a current ratio of 3.62, a quick ratio of 3.32 and a debt-to-equity ratio of 0.04.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. The business had revenue of $225.61 million for the quarter, compared to analysts’ expectations of $172.68 million. Organogenesis had a return on equity of 21.41% and a net margin of 5.32%. As a group, equities analysts expect that Organogenesis will post -0.07 EPS for the current year.

Insider Buying and Selling

In related news, Director Glenn H. Nussdorf sold 200,000 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total value of $1,028,000.00. Following the sale, the director owned 2,565,591 shares of the company’s stock, valued at $13,187,137.74. The trade was a 7.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 33.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Organogenesis

Hedge funds have recently made changes to their positions in the company. First Light Asset Management LLC grew its stake in Organogenesis by 10.6% during the third quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company’s stock worth $31,641,000 after buying an additional 720,748 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Organogenesis by 14.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 5,535,334 shares of the company’s stock valued at $28,673,000 after acquiring an additional 680,392 shares during the last quarter. Deutsche Bank AG raised its stake in shares of Organogenesis by 0.4% in the fourth quarter. Deutsche Bank AG now owns 3,297,631 shares of the company’s stock valued at $17,082,000 after acquiring an additional 13,301 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Organogenesis by 3.9% in the 2nd quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company’s stock worth $8,862,000 after acquiring an additional 91,118 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Organogenesis by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 1,786,978 shares of the company’s stock worth $9,259,000 after acquiring an additional 62,346 shares in the last quarter. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.